Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pathophysiol. Aug 15, 2014; 5(3): 178-187
Published online Aug 15, 2014. doi: 10.4291/wjgp.v5.i3.178
Barrett’s oesophagus: Evidence from the current meta-analyses
Piers Gatenby, Yuen Soon
Piers Gatenby, Division of Surgery and Interventional Science, University College London, London NW32QG, United Kingdom
Piers Gatenby, Yuen Soon, Regional Oesophagogastric Unit, Royal Surrey County Hospital, Guildford GU2 7XX, United Kingdom
Author contributions: Gatenby P concepted and designed the manuscript; acquisited and analysed data; and drafted the paper; Gatenby P and Soon Y interpreted the data and final approved of the version to be published; Soon Y concepted and revised the article critically.
Supported by Barrett’s Oesophagus Campaign; the Wexham Gastrointestinal Trust, the Childwick Trust; the R.L. St J. Harmsworth Memorial Research Fund and the David and Frederick Barclay Foundation
Correspondence to: Piers Gatenby, MA, MD, FRCS, UCL, Division of Surgery and Interventional Science, University College London, Royal Free Campus, Pond Street, London NW32QG, United Kingdom. p.gatenby@ucl.ac.uk
Telephone: +44-020-74726223 Fax: +44-020-74726224
Received: December 31, 2013
Revised: April 5, 2014
Accepted: May 29, 2014
Published online: August 15, 2014
Processing time: 246 Days and 11.6 Hours
Abstract

Guidelines have been published regarding the management of Barrett’s oesophagus (columnar-lined oesophagus). These have examined the role of surveillance in an effort to detect dysplasia and early cancer. The guidelines have provided criteria for enrolment into surveillance and some risk stratification with regard to surveillance interval. The research basis for the decisions reached with regard to cancer risk is weak and this manuscript has examined the available data published from meta-analyses up to 25th April 2013 (much of which has been published since the guidelines and their most recent updates have been written). There were 9 meta-analyses comparing patients with Barrett’s oesophagus to control populations. These have demonstrated that Barrett’s oesophagus is more common in males than females, in subjects who have ever smoked, in subjects with obesity, in subjects with prolonged symptoms of gastro-oesophageal reflux disease, in subjects who do not have infection with Helicobacter pylori and in subjects with hiatus hernia. These findings should inform public health measures in reducing the risk of Barrett’s oesophagus and subsequent surveillance burden and cancer risk. There were 8 meta-analyses comparing different groups of patients with Barrett’s oesophagus with regard to cancer risk. These have demonstrated that there was no statistically significant benefit of antireflux surgery over medical therapy, that endoscopic ablative therapy was effective in reducing cancer risk that there was similar cancer risk in patients with Barrett’s oesophagus independent of geographic origin, that the adenocarcinoma incidence in males is twice the rate in females, that the cancer risk in long segment disease showed a trend to be higher than in short segment disease, that there was a trend for higher cancer risk in low-grade dysplasia over non-dysplastic Barrett’s oesophagus, that there is a lower risk in patients with Helicobacter pylori infection and that there is a significant protective effect of aspirin and statins. There were no meta-analyses examining the role of intestinal metaplasia. These results demonstrate that guidance regarding surveillance based on the presence of intestinal metaplasia, segment length and the presence of low-grade dysplasia has a weak basis, and further consideration should be given to gender and helicobacter status, ablation of the metaplastic segment as well as the chemoprotective role of aspirin and statins.

Keywords: Barrett esophagus; Esophageal neoplasms; Meta-analysis; Review; Systematic

Core tip: The presence of intestinal metaplasia on biopsy has been regarded as a necessity for enrolment in a surveillance programme for Barrett’s oesophagus and surveillance intervals have been based on segment length and the presence or absence of dysplasia. Evidence from meta-analyses supports male gender and negative Helicobacter pylori infection status as important markers of cancer risk and of the role of aspirin, statins and ablation of the Barrett’s segment to reduce cancer risk. The evidence from meta-analyses supporting segment length and dysplasia as markers of cancer risk is poor and for intestinal metaplasia has not been shown.